Expand / Collapse search
☰
Flood Warning
until SAT 4:00 PM MST, Maricopa County
3
Flood Watch
from SUN 12:00 AM MDT until MON 5:00 AM MST, Chinle Valley, Chuska Mountains and Defiance Plateau, Northeast Plateaus and Mesas South of Hwy 264, Black Mesa Area, Northeast Plateaus and Mesas Hwy 264 Northward
Flood Watch
from SAT 11:00 PM MST until MON 5:00 AM MST, Northwest Plateau, Lake Havasu and Fort Mohave, North Phoenix/Glendale, Aguila Valley, Mazatzal Mountains, Tonopah Desert, Gila Bend, San Carlos, East Valley, Northwest Pinal County, Northwest Valley, Southeast Valley/Queen Creek, Globe/Miami, Deer Valley, Fountain Hills/East Mesa, Apache Junction/Gold Canyon, Buckeye/Avondale, Tonto Basin, Rio Verde/Salt River, South Mountain/Ahwatukee, Dripping Springs, Southeast Gila County, Pinal/Superstition Mountains, Scottsdale/Paradise Valley, New River Mesa, Sonoran Desert Natl Monument, West Pinal County, Superior, Cave Creek/New River, Central Phoenix, Eastern Cochise County below 5000 ft including Douglas/Wilcox, Upper Gila River and Aravaipa Valleys including Clifton/Safford, Southeast Pinal County including Kearny/Mammoth/Oracle, Western Pima County including Ajo/Organ Pipe Cactus National Monument, Dragoon/Mule/Huachuca and Santa Rita Mountains including Bisbee/Canelo Hills/Madera Canyon, Tucson Metro Area including Tucson/Green Valley/Marana/Vail, Tohono O'odham Nation including Sells, Baboquivari Mountains including Kitt Peak, Upper San Pedro River Valley including Sierra Vista/Benson, Chiricahua Mountains including Chiricahua National Monument, Galiuro and Pinaleno Mountains including Mount Graham, Santa Catalina and Rincon Mountains including Mount Lemmon/Summerhaven, White Mountains of Graham and Greenlee Counties including Hannagan Meadow, South Central Pinal County including Eloy/Picacho Peak State Park, Upper Santa Cruz River and Altar Valleys including Nogales, Yavapai County Mountains, Little Colorado River Valley in Navajo County, Western Mogollon Rim, Coconino Plateau, Yavapai County Valleys and Basins, Oak Creek and Sycamore Canyons, Grand Canyon Country, Little Colorado River Valley in Coconino County, Marble and Glen Canyons, Northern Gila County, White Mountains, Kaibab Plateau, Eastern Mogollon Rim, Little Colorado River Valley in Apache County

Paxlovid, Pfizer's COVID-19 pill, gets full FDA approval

By Matthew Perrone
Associated Press
Health
Published May 25, 2023 12:29 PM MST
Published May 25, 2023 12:29 PM MST
93ee5264- article

FILE - The drug Paxlovid against COVID-19 from the manufacturer Pfizer is lying on a table. (Fabian Sommer/picture alliance via Getty Images)

WASHINGTON - Pfizer received full approval on Thursday for its COVID-19 pill Paxlovid that's been the go-to treatment against the coronavirus.

More than 11 million prescriptions for Paxlovid have been dispensed since the Food and Drug Administration allowed emergency use in late 2021. The emergency status was based on early studies and was intended to be temporary pending follow-up research.

The FDA granted full approval for adults with COVID-19 who face high risks of severe disease, which can lead to hospitalization or death. That group typically includes older adults and those with common medical conditions like diabetes, asthma and obesity.

The decision allows Pfizer's drug to remain on the market indefinitely and to be marketed similarly to other drugs.

The pill is still available for children ages 12 to 17 under a separate emergency authorization.

The U.S. government has stockpiled millions of doses of Paxlovid and patients will continue to receive it at no charge, the FDA said in a statement. More than 14,000 new COVID-19 cases were reported each week last month, although most U.S. cases are no longer reported to health authorities.

What to know about Pfizer and Merck's COVID treatment pills
What to know about Pfizer and Merck's COVID treatment pills

What to know about Pfizer and Merck's COVID treatment pills

U.S. health regulators have authorized two pills against COVID-19 that Americans can take at home, developed by Pfizer and Merck.

Paxlovid is the fourth drug for COVID-19 to receive full FDA approval and the first one that is a pill. The previously approved therapies are IV or injectable drugs, typically given at clinics or hospitals.

Pfizer originally studied Paxlovid in the highest-risk COVID-19 patients: unvaccinated adults with other health problems and no evidence of prior coronavirus infection. In that group, the FDA said the drug lowered the risk of hospitalization or death by 86% when given shortly after symptoms emerged.

But that doesn’t reflect the U.S. population today, where more than 95% of people have protection from at least one vaccine dose, a prior infection or both.

In more recent studies of people who have had COVID-19, Paxlovid still significantly decreased the chance of hospitalization or death by more than 85%.

As Paxlovid became widely used in 2021, doctors and patients reported cases of COVID-19 symptoms returning several days after treatment with the drug. But the FDA said Thursday "there is not a clear association," between Pfizer’s drug and rebound cases.

That conclusion was backed by an independent panel of FDA advisers, who voted to recommend the drug's full approval at a meeting earlier this year.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

HealthCoronavirusNewsU.S.